Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Calcineurin inhibitors stimulate Kir4.1/Kir5.1 of the distal convoluted tubule to increase NaCl cotransporter
Dan-Dan Zhang, … , Dao-Hong Lin, Wen-Hui Wang
Dan-Dan Zhang, … , Dao-Hong Lin, Wen-Hui Wang
Published February 23, 2023
Citation Information: JCI Insight. 2023;8(7):e165987. https://doi.org/10.1172/jci.insight.165987.
View: Text | PDF
Research Article Cell biology Nephrology

Calcineurin inhibitors stimulate Kir4.1/Kir5.1 of the distal convoluted tubule to increase NaCl cotransporter

  • Text
  • PDF
Abstract

We examine whether calcineurin or protein phosphatase 2B (PP2B) regulates the basolateral inwardly rectifying potassium channel Kir4.1/Kir5.1 in the distal convoluted tubule (DCT). Application of tacrolimus (FK506) or cyclosporine A (CsA) increased whole-cell Kir4.1/Kir5.1-mediated K+ currents and hyperpolarized the DCT membrane. Moreover, FK506-induced stimulation of Kir4.1/Kir5.1 was absent in kidney tubule–specific 12 kDa FK506-binding protein–knockout mice (Ks-FKBP-12–KO). In contrast, CsA stimulated Kir4.1/Kir5.1 of the DCT in Ks-FKBP-12–KO mice, suggesting that FK506-induced stimulation of Kir4.1/Kir5.1 was due to inhibiting PP2B. Single-channel patch-clamp experiments demonstrated that FK506 or CsA stimulated the basolateral Kir4.1/Kir5.1 activity of the DCT, defined by NPo (a product of channel number and open probability). However, this effect was absent in the DCT treated with Src family protein tyrosine kinase (SFK) inhibitor or hydroxyl peroxide. Fluorescence imaging demonstrated that CsA treatment increased membrane staining intensity of Kir4.1 in the DCT of Kcnj10fl/fl mice. Moreover, CsA treatment had no obvious effect on phosphorylated NaCl cotransporter (pNCC) expression in Ks-Kir4.1–KO mice. Immunoblotting showed acute FK506 treatment increased pNCC expression in Kcnj10fl/fl mice, but this effect was attenuated in Ks-Kir4.1–KO mice. In vivo measurement of thiazide-induced renal Na+ excretion demonstrated that FK506 enhanced thiazide-induced natriuresis. This effect was absent in Ks-FKBP-12–KO mice and blunted in Ks-Kir4.1–KO mice. We conclude that inhibition of PP2B stimulates Kir4.1/Kir5.1 of the DCT and NCC and that PP2B inhibition–induced stimulation of NCC is partially achieved by stimulation of the basolateral Kir4.1/Kir5.1.

Authors

Dan-Dan Zhang, Xin-Peng Duan, Kerim Mutig, Franziska Rausch, Yu Xiao, Jun-Ya Zheng, Dao-Hong Lin, Wen-Hui Wang

×

Figure 1

Inhibition of calcineurin (PP2B) increases the basolateral K+ currents in the DCT.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of calcineurin (PP2B) increases the basolateral K+ currents i...
(A) A set of whole-cell recordings shows the effect of FK506 (10 μM) and CsA (200 nM) on Kir4.1/Kir5.1-mediated K+ currents in the DCT. The Kir4.1/Kir5.1-mediated whole-cell K+ currents were measured with a step protocol from −100 to 60 mV. The vehicle, FK506, or CsA was added in the bath for 10 minutes. (B) A scatterplot summarizing the results of above experiments in which Ba2+-sensitive K+ currents (Kir4.1/Kir5.1) of the DCT were measured at −60 mV. Each data point from male (blue circles) or female mice (red triangles) is presented for 2 separate columns, and the mean value ± SEM (including data from male and female mice) is shown in the middle. Significance is determined by 1-way ANOVA. (C) A set of recordings shows Kir4.1/Kir5.1-mediated whole-cell K+ currents in DCT of male Fkbp1afl/fl and male Ks-FKBP12–KO mice treated with FK506 (0.75 mg/kg BW) or CsA (3 mg/kg BW) by peritoneal injection 30 minutes before the experiment, respectively. The whole-cell K+ currents were measured with a ramp protocol from −100 to 100 mV. (D) A scatterplot summarizing the results of experiments in which Kir4.1/Kir5.1-mediated whole-cell K+ currents of the DCT were measured at −60 mV. Mean values and SEM are shown on the left of each column. A symmetric 140 mM KCl solution was used for the bath and the pipette. Significant difference as determined by 2-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts